• NF 340: Selective P2Y11 Antagonist for GPCR Pathway Research

  2026-07-07

  NF 340 is a potent, selective antagonist of human P2Y11 receptors, enabling precise dissection of purinergic and GPCR signaling in immunology and cancer models. Research confirms its utility in reversing QPRT-driven cell invasiveness and inflammation pathway activation. The product's chemical stability and defined action profile make it a valuable tool for evidence-based experimental design.

• Ruxolitinib Phosphate: Advancing JAK/STAT Pathway Translatio

  2026-07-07

  Explore how Ruxolitinib phosphate (INCB018424) empowers translational researchers to unravel the complexities of JAK/STAT signaling in inflammatory and oncologic models. This article contextualizes recent mechanistic discoveries, including mitochondrial fission and cell death in solid tumors, while offering actionable protocol guidance and strategic perspective for next-generation pathway modulation.

• Ruxolitinib Phosphate (INCB018424): Applied JAK/STAT Pathway

  2026-07-06

  Leverage Ruxolitinib phosphate (INCB018424) for precise JAK/STAT pathway modulation in models of inflammation and advanced oncology. This guide details experimental workflows, troubleshooting strategies, and unique mechanistic insights to maximize reproducibility in cytokine signaling inhibition research.

• Upd2 Cytokine Orchestrates Disciplined Tracheal Stem Cell Mi

  2026-07-06

  This study uncovers how the Drosophila fat body-derived cytokine Upd2 governs the collective, directional migration of tracheal stem cells via JAK/STAT signaling and planar cell polarity. The findings highlight inter-organ communication and vesicular trafficking as crucial for maintaining tissue homeostasis, offering a mechanistic framework relevant to stem cell biology and regenerative research.

• Myriocin as a Serine Palmitoyltransferase Inhibitor in Lipid

  2026-07-05

  Myriocin is redefining sphingolipid metabolism research as a selective serine palmitoyltransferase inhibitor, with proven efficacy in experimental models of metabolic, oncologic, and neurological dysfunction. Its robust inhibition profile and translational track record make it indispensable for advanced bench studies targeting lipid signaling pathways.

• BAPTA-AM in Neurodegeneration: Mechanistic Insights and Adva

  2026-07-04

  Explore how BAPTA-AM, a leading cell-permeable calcium chelator, enables advanced dissection of calcium-driven neurodegeneration and necroptosis. This article delivers a mechanistic deep dive and protocol innovations, setting it apart from standard assay guides.

• β-Elemene Inhibits Adipogenesis via AMPK Pathway Activation

  2026-07-03

  This study demonstrates that β-Elemene suppresses lipid accumulation and adipogenesis in 3T3-L1 preadipocytes by activating the AMPK pathway. The findings support β-Elemene's utility as a tool compound for probing metabolic and obesity-related mechanisms in vitro, with implications for future obesity research and drug development.

• Thymoquinone (SKU C5035): Reliable Probe for Cardiotoxicity

  2026-07-03

  This article provides an evidence-based, scenario-driven guide to using Thymoquinone (SKU C5035) in cell viability and cardiotoxicity studies. Drawing on peer-reviewed findings and workflow best practices, it addresses common lab challenges and demonstrates how APExBIO's Thymoquinone offers robust, reproducible solutions for biomedical researchers.

• SIRT4-Regulated Glutamine Metabolism Mitigates Liver Fibrosi

  2026-07-02

  This article explains how the reference study establishes SIRT4-mediated regulation of glutamine metabolism in hepatic stellate cells as a therapeutic target for liver fibrosis. By detailing mechanisms of GDH inhibition and the anti-fibrotic effects of SIRT4, it highlights new avenues for mitochondrial biogenesis research and metabolic disease intervention.

• CTCF Drives PDAC Progression via FLG-AS1 and Macrophage Modu

  2026-07-02

  This study reveals how CTCF promotes pancreatic ductal adenocarcinoma (PDAC) growth by orchestrating epigenetic regulation through FLG-AS1 and influencing tumor-associated macrophage polarization. Using multi-omics approaches, the work uncovers a novel CTCF-IGF2BP2-CSF1 axis, highlighting therapeutic opportunities for immune modulation in PDAC.

• Vitamin C Inhibits Cochlear Cell Senescence via ROS/NF-κB Pa

  2026-07-01

  The reference study provides new evidence that vitamin C (ascorbic acid) mitigates D-galactose-induced senescence in cochlear hair cells by suppressing the ROS/NF-κB signaling pathway. These findings suggest a mechanistic basis for vitamin C's protective role against age-related hearing loss, offering a potential translational direction for future interventions.

• Repurposing Lopinavir: Inhibition of MERS-CoV in Cell Cultur

  2026-07-01

  de Wilde et al. systematically screened FDA-approved drugs and identified Lopinavir (ABT-378) as a potent inhibitor of MERS-CoV replication in vitro. This approach highlights the value of drug repurposing for rapid antiviral response and informs future research targeting emerging coronaviruses.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Re

  2026-06-30

  Xiao et al. (2024) demonstrate how lysosomal accumulation of 25-hydroxycholesterol (25HC) reprograms tumor-associated macrophages (TAMs) toward an immunosuppressive phenotype via AMPKa and STAT6 activation. This work uncovers a metabolic checkpoint that could be targeted to enhance anti-tumor immunity, with significant implications for future cancer immunotherapy strategies.

• NINJ1 Nanodisc Rings Drive Membrane Rupture in Pyroptosis

  2026-06-30

  The referenced study uncovers how NINJ1 forms nanodisc-like rings that mediate plasma membrane rupture during pyroptotic cell death. This mechanistic insight advances our understanding of lytic cell death pathways and has implications for structural studies of membrane-associated proteins.

• Rapamycin (Sirolimus): Precision mTOR Inhibition in Bench Re

  2026-06-29

  Rapamycin (Sirolimus) delivers unparalleled specificity for mTOR inhibition, enabling reproducible dissection of AKT/mTOR, ERK, and JAK2/STAT3 pathways across cancer, immunology, and mitochondrial disease models. This guide translates cutting-edge literature and recent neurogenesis research into actionable protocols, troubleshooting, and advanced workflow strategies for maximizing data quality with APExBIO’s A8167 formulation.

16131 records 1/1076 page Next 12345 下5页 Last page